BBP-418: LGMD2I/R9 FDA decision
BridgeBio reports BBP-418 under FDA priority review for LGMD2I/R9, with a November 27, 2026 target, reconfirmed in its October FORTIFY update. The regulatory event is separate from already reported clinical and exploratory cardiac findings.
BridgeBio Pharma / BBIODrug catalystsRegulatory decisionTarget: 2026-11-27
What matters
Follow the exact application, indication and requested label. An FDA decision concerns the drug program, while the company’s stock also reflects its other assets and business.
- Do not generalize an LGMD2I/R9 application to every muscular dystrophy genotype.
- Exploratory biomarkers and a sponsor assertion of disease modification do not establish FDA approval.
Primary evidence
FDA target 2026-11-27 — not a guaranteed decision date
BridgeBio · October target confirmation and FORTIFY contextPublished 2026-10-05
Potential outcome market
Will FDA approve BBP-418 for FKRP-related limb-girdle muscular dystrophy type 2I/R9 by a separately fixed evidence cutoff?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.